retatrutide benefits research Substack Series 3 of 6: – The Next Frontier in Longevity and Metabolic Health Retatrutide Weight Loss Treatment Explained

Orforglipron, the easier-to-use alternative to injectable weight-loss and diabetes medications, is a promising new tool with improved convenience for providers and patients

Dont assume everything will work itself outit probably wont without some effort on your part

Rare but serious risks include: Pancreatitis : Severe abdominal pain should prompt immediate medical attention Gallbladder problems : Rapid weight loss can increase gallstone risk Diabetic retinopathy complications : In people with existing eye disease, rapid glucose improvement may temporarily worsen retinopathy, particularly with semaglutide [14] [15] Hypoglycaemia : Low blood sugar is uncommon with GLP-1 agonists alone but can occur if combined with insulin or sulphonylureas [17] [18] GLP-1 agonists are not recognised to directly cause dangerous blood pressure drops (hypotension) in most patients

Clinical scenarios warranting consideration of GLP-1 therapy include: Type 2 diabetes management : Per ADA 2024 Standards of Care, GLP-1 RAs may be considered as initial therapy in patients with established atherosclerotic cardiovascular disease (ASCVD), high ASCVD risk, chronic kidney disease (CKD), or heart failure, or as add-on therapy when glycemic targets aren't met Established cardiovascular disease : Several GLP-1 receptor agonists have demonstrated cardiovascular risk reduction in patients with type 2 diabetes and established ASCVD Chronic kidney disease : While SGLT2 inhibitors are generally prioritized for CKD with type 2 diabetes when eGFR allows, GLP-1 RAs may provide complementary benefits Obesity with complications : When lifestyle interventions produce insufficient weight loss in patients with obesity-related comorbidities Important safety considerations include: Contraindications : Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2